Inhalable drug given green light

Inhalable drug given green light
The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment. INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people ... read more
Source: Parkinson’s Life EUPublished on 2019-01-09By admin